A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.

Hayashi, Kazumi; Tamura, Miho; Nagasaki, Eijiro; Yoshii, Yukiko; Ishigaki, Takayuki; Kazama, Takashi; Kamio, Makiko; Nogi, Hiroko; Toriumi, Yasuo; Takeyama, Hiroshi; Yano, Shingo

BACKGROUND/AIM Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer. PATIENTS AND METHODS Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected. RESULTS No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital. CONCLUSION Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19.